Publications

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Nature Medicine

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, …

Nature 639(8056), 1042–1051

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, … Park W, …

Nature 618(7963), 144–150

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, … Park W, …

Cancer Immunology, Immunotherapy 69(7), 1177–1187

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, …

The Lancet Oncology 20(6), 837–848

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, …

Journal for Immunotherapy of Cancer 7(1), 131